Harvard Management Company’s Dyne Therapeutics DYN Stock Holding History

Harvard Management Company’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-107,252	Closed	-$1.24M	–	38
2023 Q1	$1.24M	Hold	107,252	–	–	0.13%	38
2022 Q4	$1.24M	Hold	107,252	–	–	0.15%	39
2022 Q3	$1.36M	Hold	107,252	–	–	0.17%	39
2022 Q2	$737K	Hold	107,252	–	–	0.09%	42
2022 Q1	$1.03M	Hold	107,252	–	–	0.1%	40
2021 Q4	$1.27M	Hold	107,252	–	–	0.12%	42
2021 Q3	$1.74M	Hold	107,252	–	–	0.1%	36
2021 Q2	$2.26M	Hold	107,252	–	–	0.13%	35
2021 Q1	$1.67M	Hold	107,252	–	–	0.09%	37
2020 Q4	$2.25M	Hold	107,252	–	–	0.12%	27
2020 Q3	$2.17M	Buy	+107,252	New	+$2.35M	0.12%	24

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harvard Management Company's DYN Position: Q2 2023 in Review

Harvard Management Company sold out of Dyne Therapeutics (DYN) in Q2 2023, closing a stake of 107,252 shares — an estimated $1.24M sold.

Harvard Management Company first reported a position in DYN in Q3 2020 and held it in 11 quarters. The position peaked at $2.26M in Q2 2021. 118 funds tracked by Wall St. Rank hold DYN as of Q2 2023.

Harvard Management Company reported no remaining Dyne Therapeutics position as of Q2 2023 after selling out during the quarter.
Harvard Management Company sold 107,252 Dyne Therapeutics shares in Q2 2023, an estimated $1.24M.
Harvard Management Company first reported a position in Dyne Therapeutics in Q3 2020 and held it in 11 quarters.
Harvard Management Company's Dyne Therapeutics position peaked at $2.26M in Q2 2021.
118 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2023.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.